White Rose Technology Seedcorn Fund, managed by Aberdeen Asset Managers, has invested £250,000 as part of a £550,000 funding round for Pro-Cure Therapeutics Ltd, a company which is developing potential treatments for prostate cancer from stem cell research.
DVI Equity Partners, Frontline Ventures and Enterprise Ireland also take part
Newcomer Target Global and existing investor Round Hill Ventures also take part in the round
GP invests €7.3m in the France-based point-of-sale merchandising equipment provider
Azimut appoints Jeffry Brown as CEO of AACP; Brown previously worked at Dyal Capital Partners